We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bladder Cancer Cell Receptor Detectable in Urine and Prostatic Fluid

By Labmedica staff writers
Posted on 17 Mar 2008
A new cell receptor was found on cancerous cells in patients suffering from bladder cancer. When the receptor sloughs off the cancer cells, it can be found in urine and prostatic fluid (in men). The first of its kind, the cell receptor offers great potential as a non-invasive, easy-to-make dipstick or rapid urine test that could transform the screening and diagnosis process for bladder cancer

The receptor was discovered by scientists at the Medical University of South Carolina for Research and Development (MUSC; Charleston, SC, USA). Current tests for bladder cancer are accurate for only 40% of diagnoses. MUSC's new test has demonstrated 90% accuracy (100% specificity) in human urine samples of patients with various degrees of bladder cancer, confirming the newly discovered cell receptor's efficacy in diagnosing that cancer.

Patients undergo bladder cancer screening if they are determined to have certain risk factors including a previous diagnosis of bladder cancer, birth defects of the bladder, advanced age (over 55), or work-related exposure to certain chemicals. Bladder cancer affects men more than women, as well as whites more than other ethnicities, according to the American Cancer Society. The organization estimates that of the approximately 69,000 new bladder cancer cases in the United States this year, almost 52,000 will be in men.

Current studies report that patients with successfully treated bladder cancer still have a 50-80% recurrence rate, making this potential urine-based test perfect for home cancer recurrence monitoring. For the methods most routinely used to detect or monitor bladder cancer, convenience, comfort, and pain are issues important to patients. The new diagnostic test from MUSC could eliminate the need for invasive tests such as cystoscopy and biopsies that can be painful and even cause medical complications.


Related Links:
Medical University of South Carolina for Research and Development

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T

Latest Clinical Chem. News

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
17 Mar 2008  |   Clinical Chem.

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
17 Mar 2008  |   Clinical Chem.

Low-Cost Portable Screening Test to Transform Kidney Disease Detection
17 Mar 2008  |   Clinical Chem.